WallStSmart

Merck & Company Inc (MRK)vsSenti Biosciences Inc (SNTI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 295504441% more annual revenue ($65.01B vs $22,000). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9

SNTI

Avoid

14

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued

Intrinsic value data unavailable for SNTI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

SNTI0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

SNTI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$29.75M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-218.1%2/10

ROE of -218.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bull Case : SNTI

SNTI has a balanced fundamental profile.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : SNTI

The primary concerns for SNTI are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

SNTI carries more volatility with a beta of 2.12 — expect wider price swings.

MRK is growing revenue faster at 5.0% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (59/100 vs 14/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Senti Biosciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Senti Biosciences Inc (SNTI) is an innovative biotechnology company at the forefront of synthetic biology, dedicated to pioneering next-generation cell and gene therapies. Utilizing its proprietary GeneCircuit platform, the company is developing programmable therapies aimed at treating a spectrum of diseases, including cancer and genetic disorders, thereby enhancing the precision of personalized medicine. With a robust development pipeline and strong strategic partnerships, Senti is strategically positioned to drive advancements in engineered cell therapies, offering transformative solutions to address critical unmet medical needs in the biopharmaceutical sector.

Want to dig deeper into these stocks?